

Bivatuzumab

Cat. No.:	HY-P99281
CAS No.:	214559-60-1
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirectioned CIK cells ^[1] .
In Vitro	Bivatuzumab (10 µg/mL) stains CD44v6 in STS cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Leuci V, et al. CD44v6 as innovative sarcoma target for CAR-redirectioned CIK cells. Oncoimmunology. 2018 Feb 15;7(5):e1423167.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA